2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide

2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide Suppliers list
Company Name: MQ (shanghai) Pharmaceuticals Co., Ltd.  
Tel: 13761635123
Email: sales@linyuepharm.com
Company Name: Guangzhou Younan Technology Co., Ltd  
Tel: 020-82000279 18988941452
Email: YN_research@163.com
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Email: 486064515@qq.com
Company Name: Shanghai Huasige Pharmaceutical Technology Co., LTD  
Tel: 13611612777
Email: 3627377363@qq.com
Company Name: Aikon International Limited  
Tel: 025-58859352 18651614124
Email: 2881516338@qq.com
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide Basic information
Product Name:2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide
Synonyms:2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide;IRF1-IN-2;2-Methoxy-N-(4-(pyrrolidin-1-ylsulfonyl)phenyl)benzamide;2-Methoxy-N-[4-(pyrrolidine-1-sulfonyl)-phenyl]-benzamide
CAS:708245-32-3
MF:C18H20N2O4S
MW:360.4274
EINECS:
Product Categories:
Mol File:708245-32-3.mol
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide Structure
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide Chemical Properties
form Solid
color White to off-white
Safety Information
MSDS Information
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide Usage And Synthesis
UsesIRF1-IN-2 (Compound I-19) is an IRF1 inhibitor. IRF1-IN-2 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-2 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1; inhibits the Pho of TKB1, upregulates GPX4 and downregulates FACL4). IRF1-IN-2 has a protective effect on ionizing radiation-induced inflammatory skin injury[1].
in vivo

IRF1-IN-2 pretreatment (100μg/d, s.c., one every other day before irradiation) has a potential protective effect in 35 Gy radiation-induced inflammatory skin injury mice[1].

Animal Model:Radiogenic skin injury mice (intraperitoneal injection of pentobarbital sodium (1%, 30 mg/kg), 35 Gy at the dose rate of 1000 cGy/min by a 6-MeV electron beam)[1]
Dosage:100 μg/d
Administration:Subcutaneous injection (s.c.), one every other day before irradiation, pretreatment
Result:Showed a significant reduction in acute skin inflammatory manifestations, such as erythema and exudation.
Showed protective effects on the function and structural integrity of radiation-induced lesions to the claws.
IC 50PARP-1; IL-1; Caspase-1
References[1] Geng, et al. Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. Cell Mol Immunol. 2024 Aug;21(8):856-872. DOI:10.1038/s41423-024-01185-3
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide Preparation Products And Raw materials
Tag:2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide(708245-32-3) Related Product Information
Benzamide, 2-methoxy-N-[[4-[[(methylamino)carbonyl]amino]phenyl]sulfonyl]- 3-methoxy-N-{4-[(2-phenylethyl)sulfamoyl]phenyl}benzamide Benzamide, N-[4-methyl-3-(4-morpholinylsulfonyl)phenyl]-2-phenoxy- N-(4-ethoxyphenyl)-4-{[(phenylsulfonyl)anilino]methyl}benzamide N-[4-(1-azepanylsulfonyl)phenyl]-3,4,5-trimethoxybenzamide N-(3-methoxyphenyl)-3-morpholin-4-ylsulfonylbenzamide